MRK vs. NBIX
MRK (Merck & Co., Inc.) and NBIX (Neurocrine Biosciences, Inc.) are both stocks. Both are in the Healthcare sector — MRK in Drug Manufacturers - General, NBIX in Drug Manufacturers - Specialty & Generic. Over the past 10 years, MRK returned 11.59%/yr vs 13.16%/yr for NBIX. At a 0.22 correlation, their price movements are largely independent.
Performance
MRK vs. NBIX - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, MRK achieves a 13.94% return, which is significantly higher than NBIX's 12.64% return. Over the past 10 years, MRK has underperformed NBIX with an annualized return of 11.59%, while NBIX has yielded a comparatively higher 13.16% annualized return.
MRK
- 1D
- -1.42%
- 1M
- 4.94%
- YTD
- 13.94%
- 6M
- 20.60%
- 1Y
- 50.79%
- 3Y*
- 5.87%
- 5Y*
- 12.81%
- 10Y*
- 11.59%
NBIX
- 1D
- -1.81%
- 1M
- -0.97%
- YTD
- 12.64%
- 6M
- 4.55%
- 1Y
- 27.80%
- 3Y*
- 18.64%
- 5Y*
- 10.13%
- 10Y*
- 13.16%
MRK vs. NBIX - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
MRK Merck & Co., Inc. | 13.94% | 9.79% | -6.26% | 1.01% | 49.42% | 1.75% | -7.20% | 22.27% | 39.95% | -1.49% |
NBIX Neurocrine Biosciences, Inc. | 12.64% | 3.90% | 3.60% | 10.31% | 40.24% | -11.14% | -10.83% | 50.53% | -7.96% | 100.49% |
Correlation
The correlation between MRK and NBIX is 0.30, which is low. Their price movements are largely independent, making them effective diversification partners.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | 0.30 |
Correlation (3Y) Calculated over the trailing 3-year period | 0.20 |
Correlation (5Y) Calculated over the trailing 5-year period | 0.20 |
Correlation (10Y) Calculated over the trailing 10-year period | 0.23 |
Correlation (All Time) Calculated using the full available price history since May 23, 1996 | 0.22 |
Fundamentals
MRK:
$294.29B
NBIX:
$16.52B
MRK:
$3.58
NBIX:
$6.53
MRK:
33.21
NBIX:
24.46
MRK:
0.03
NBIX:
0.48
MRK:
4.52
NBIX:
5.27
MRK:
6.41
NBIX:
4.85
MRK:
$65.59B
NBIX:
$3.10B
MRK:
$49.79B
NBIX:
$3.05B
MRK:
$22.69B
NBIX:
$881.20M
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
MRK vs. NBIX — Risk / Return Rank
MRK
NBIX
MRK vs. NBIX - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Merck & Co., Inc. (MRK) and Neurocrine Biosciences, Inc. (NBIX). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| MRK | NBIX | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | +0.99 | ||
| Sortino ratioReturn per unit of downside risk | +1.43 | ||
| Omega ratioGain probability vs. loss probability | 1.33 | 1.19 | +0.15 |
| Calmar ratioReturn relative to maximum drawdown | 4.49 | 1.34 | +3.15 |
| Martin ratioReturn relative to average drawdown | 11.22 | 2.94 | +8.28 |
Loading charts...
Drawdowns
MRK vs. NBIX - Drawdown Comparison
The maximum MRK drawdown since its inception was -68.61%, smaller than the maximum NBIX drawdown of -97.21%. Use the drawdown chart below to compare losses from any high point for MRK and NBIX.
Loading charts...
Drawdown Indicators
| MRK | NBIX | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -68.61% | -97.21% | +28.60% |
Max Drawdown (1Y)Largest decline over 1 year | -11.37% | -20.90% | +9.53% |
Max Drawdown (3Y)Largest decline over 3 years | -43.44% | -42.89% | -0.55% |
Max Drawdown (5Y)Largest decline over 5 years | -43.44% | -42.89% | -0.55% |
Max Drawdown (10Y)Largest decline over 10 years | -43.44% | -46.39% | +2.95% |
Current DrawdownCurrent decline from peak | -5.03% | -4.54% | -0.49% |
Average DrawdownAverage peak-to-trough decline | -18.83% | -43.84% | +25.01% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 4.54% | 9.49% | -4.95% |
Volatility
MRK vs. NBIX - Volatility Comparison
Merck & Co., Inc. (MRK) and Neurocrine Biosciences, Inc. (NBIX) have volatilities of 9.57% and 9.63%, respectively, indicating that both stocks experience similar levels of price fluctuations. This suggests that the risk associated with both stocks, as measured by volatility, is nearly the same. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| MRK | NBIX | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 9.57% | 9.63% | -0.06% |
Volatility (6M)Calculated over the trailing 6-month period | 18.04% | 23.91% | -5.87% |
Volatility (1Y)Calculated over the trailing 1-year period | 27.18% | 31.38% | -4.20% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 23.66% | 32.73% | -9.07% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 22.96% | 39.13% | -16.17% |
Dividends
MRK vs. NBIX - Dividend Comparison
MRK's dividend yield for the trailing twelve months is around 2.79%, while NBIX has not paid dividends to shareholders.
| Position | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
MRK Merck & Co., Inc. | 2.79% | 3.12% | 3.14% | 2.72% | 2.52% | 3.41% | 3.03% | 2.48% | 2.60% | 3.36% | 3.14% | 3.43% |
NBIX Neurocrine Biosciences, Inc. | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Financials
MRK vs. NBIX - Financials Comparison
This section allows you to compare key financial metrics between Merck & Co., Inc. and Neurocrine Biosciences, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
MRK vs. NBIX - Profitability Comparison
MRK - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Merck & Co., Inc. reported a gross profit of 13.34B and revenue of 16.29B. Therefore, the gross margin over that period was 81.9%.
NBIX - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Neurocrine Biosciences, Inc. reported a gross profit of 800.70M and revenue of 814.50M. Therefore, the gross margin over that period was 98.3%.
MRK - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Merck & Co., Inc. reported an operating income of -1.88B and revenue of 16.29B, resulting in an operating margin of -11.6%.
NBIX - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Neurocrine Biosciences, Inc. reported an operating income of 193.40M and revenue of 814.50M, resulting in an operating margin of 23.7%.
MRK - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Merck & Co., Inc. reported a net income of -4.24B and revenue of 16.29B, resulting in a net margin of -26.0%.
NBIX - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Neurocrine Biosciences, Inc. reported a net income of 197.90M and revenue of 814.50M, resulting in a net margin of 24.3%.
Frequently Asked Questions
MRK and NBIX have a correlation of 0.30, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
NBIX has higher volatility (9.63%) compared to MRK (9.57%). In terms of maximum drawdown, MRK dropped -68.61% vs NBIX's -97.21%.
MRK currently has the higher Sharpe Ratio (1.88 vs 0.89), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for MRK and NBIX
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer